You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Alkoxylamine nucleosides for sequencing by synthesis

    SBC: Genomechanix, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): This Phase I STTR proposal seeks funding to transfer technology from the Foundation for Applied Molecular Evolution (nonprofit) to GenoMechanix (for-profit) relating to a strategy for doing "sequencing by synthesis". This strategy involves the incorporation, in a template-directed polymerization step, of a nucleoside triphosphate having its 3'-hydroxyl group ...

    STTR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
  2. A Mechanistically Novel Antibiotic for Anthrax

    SBC: Nanopharma            Topic: N/A

    DESCRIPTION (provided by applicant): Anthrax is an infectious illness that has been known for many years, largely in rural settings, but since the terrorist attacks of 9-11, has recently emerged as a major national security concern. Bacillus anthracis, the causative agent of anthrax, exists naturally in various forms and is now considered a bioterrorism agent. There is fear that this microbe coul ...

    STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health
  3. An Advanced Biosensor for Molecular Interaction Studies.

    SBC: MOLECULAR SENSING, INC.            Topic: NIGMS

    DESCRIPTION (provided by applicant): Molecular interactions form the foundation of biology and chemistry. They are central to life itself and determine catalytic activity, cellular function, and therapeutic efficacy. The vast majority of diagnostic procedures depend on some type of specific molecular interaction. Therefore, the ability to perform pure liquid-phase molecular binding analysis at hi ...

    STTR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  4. A Novel Protection Device for Shock Wave Lithotripter

    SBC: Genognomon, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): The shock wave lithotripsy (SWL) was first introduced successfully in clinical treatment in the earlier 1980s by Dornier Medical System in Germany. Now it has become the modality for urolithiasis diseases. However, SWL also causes acute renal injury, such as hemorrhage, hematoma, edema and enlargement of kidney. Although most patients recover well following ...

    STTR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
  5. Antiatherogenic Properties of tert-Butylhydroquinone

    SBC: BIOINVENTIONS, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): Atherosclerosis is the underlying cause of most cardiovascular disease and considerable evidence supports the role of hypercholesterolemia as a risk factor for this disease. In preliminary work, we found that tertiary-butyl hydroquinone (TBHQ), at a dose lower than approved for human use, was effective in reducing plasma levels of both total cholesterol and tri ...

    STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health
  6. Antisense Treatment for Thalassemia. Preclinical study.

    SBC: ERCOLE BIOTECH, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): The ultimate goal of this project is treatment of beta-thalassemia, a genetic blood disease, with antisense oligonucleotides. The project is based on the technology developed by the PI in which antisense oligonucleotides are used to restore correct functioning of a defective gene rather than, as commonly practiced, to inhibit the expression of an undesirable ge ...

    STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health
  7. Antisense Treatment for Thalassemia. Preclinical study.

    SBC: ERCOLE BIOTECH, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): The ultimate goal of this project is treatment of beta-thalassemia, a genetic blood disease, with antisense oligonucleotides. The project is based on the technology developed by the PI in which antisense oligonucleotides are used to restore correct functioning of a defective gene rather than, as commonly practiced, to inhibit the expression of an undesirable ge ...

    STTR Phase II 2005 Department of Health and Human ServicesNational Institutes of Health
  8. A Worldwide Research Network of Dynamic Cardiac Images

    SBC: HEART IMAGING TECHNOLOGIES, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): This is a Phase I of a fast-track STTR application submitted in response to Program Announcement PA-03-001 ("Knowledge Integration across Distributed Heterogeneous Data Sources"). We propose a collaborative effort between Heart Imaging Technologies, LLC (HeartIT) and Duke University's Cardiovascular Magnetic Resonance Center (DCMRC). The goal of the collaborati ...

    STTR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
  9. Bioreactor for Engineered Bioartificial Tissues (BATS)

    SBC: Flexcell International Corporation            Topic: N/A

    DESCRIPTION (provided by applicant): Few commercial bioreactors are available for the culture of three dimensional (3D) tissues. Flexcell's strategy is to provide a commercial bioreactor allowing ease of operation to produce molded 3D tissue constructs in cell- populated matrix gels of variable geometries with controlled nutrient perfusion and mechanical stimulation. This design is based on a vali ...

    STTR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
  10. Bragg selectors of transversal modes for high power lasers

    SBC: OPTIGRATE CORPORATION            Topic: N/A

    The objective of this proposal is to demonstrate the novel type of mode selection for high power lasers for target tracking and interception. In Phase I, LPTI proved the concept of volume Bragg gratings (VBGs), which were recorded in photo-thermo-refractive (PTR) glass, as effective selectors of transverse modes for pulsed neodymium laser. Dramatic narrowing of angular divergence of Nd:YAG laser w ...

    STTR Phase I 2004 Department of DefenseMissile Defense Agency
US Flag An Official Website of the United States Government